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ABSTRACT
Introduction: Delayed-release dimethyl fumarate
(DMF; also known as gastro-resistant DMF)
demonstrated clinical and neuroradiologic
efficacy and safety in the Phase 3 DEFINE and
CONFIRM trials, and in the extension study
(ENDORSE), in patients with relapsing–remitting
multiple sclerosis (RRMS). This post hoc analysis
assessed DMF efficacy in newly diagnosed patients
with RRMS with 6-year minimum follow-up.
Methods: Patients randomized in DEFINE/
CONFIRM to DMF 240 mg twice (BID) or
thrice daily (TID) continued on same dosage
in ENDORSE. Patients randomized to placebo
(PBO) or glatiramer acetate (CONFIRM only)
were re-randomized to DMF BID or TID. Results
for DMF BID (approved dosage) are reported.
Newly diagnosed patients were diagnosed
within 1 year prior to DEFINE/CONFIRM entry
and either treatment-naive or previously treated
with corticosteroids alone.
Results: The newly diagnosed population
included 144 patients continuously treated
with DMF BID in DEFINE/CONFIRM and
ENDORSE (DMF/DMF) and 85 treated with
PBO for 2 years in DEFINE/CONFIRM followed
by 4 years of DMF BID in ENDORSE (PBO/DMF).
At 6 years (ENDORSE Year 4), the annualized
relapse rates [ARR; 95% confidence interval (CI)]
were 0.137 (0.101, 0.186) and 0.168 (0.113,
0.252) for DMF/DMF and PBO/DMF,
respectively; representing 19% risk reduction
(P = 0.3988). PBO/DMF patients demonstrated
improvements in ARR after switching to DMF in
ENDORSE: 0.260 (0.182, 0.372) for Years 0–2
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(DEFINE/CONFIRM) and 0.102 (0.064, 0.163)
for Years 3–6 (ENDORSE), representing 61% risk
reduction for Years 3–6 versus Years 1–2
(P\0.0001). The proportion of patients with
24-week confirmed disability progression (95%
CI) at 6 years was 15.7% (10.3%, 23.7%) in
DMF/DMF and 24.3% (15.9%, 36.2%) in PBO/
DMF, representing 49% risk reduction versus
PBO/DMF (P = 0.0397).
Conclusion: Long-term DMF treatment
demonstrated strong and sustained efficacy in
newly diagnosed patients. Results suggest
greater clinical benefits with earlier initiation
of treatment in this patient population.
Funding: Biogen.
Trial registration: ClinicalTrials.gov identifiers,
NCT00835770 (ENDORSE); NCT00420212
(DEFINE); NCT00451451 (CONFIRM).
Keywords: Delayed-release dimethyl fumarate;
Efficacy; Multiple sclerosis; Newly diagnosed;
Safety
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory,
demyelinating, neurodegenerative disease
affecting the central nervous system [1–3].
More than 2 million people worldwide are
affected by this disease, with more than
two-thirds of these patients suffering from the
relapsing–remitting MS (RRMS) form of the
disease [4, 5]. Patients with relapsing forms
of MS experience sporadic relapses that
are typically associated with neurologic
impairment, disability, and a decrease in
overall health and quality of life [5, 6]. There
is extensive variability in the frequency,
duration, and severity of symptoms, as well as
the extent of recovery [5]. MS begins with the
formation of acute inflammatory lesions. Such
lesions are often clinically ‘silent’ and have
been estimated to be about 10 times more
frequent than episodes of clinical worsening
[7, 8]. This subclinical tissue damage can be
visualized by magnetic resonance imaging
(MRI). Early in the disease process, the
inflammatory activity eventually becomes
clinically manifested as a clinically isolated
syndrome (CIS)—the first episode of clinically
apparent neurologic episodes.
The degenerative processes associated with
the progression of the disease include axonal
loss in lesions, diffuse damage to white matter
distant from areas shown to be involved by
histopathology or MRI, and atrophy of deep
and cortical grey matter. The later stages of
relapsing MS are associated with the
accumulation of neuronal loss and gliosis [7].
Therefore, initiating treatment early in the
course of relapsing MS could potentially slow
disease progression. In fact, clinical trials with
interferon b and glatiramer acetate (GA) have
shown that early treatment was associated with
improved outcomes, including a prolonged
time to conversion from CIS to clinically
definite MS (CDMS) and a reduction in the
number and volume of lesions detected by MRI
[9–16].
Delayed-release dimethyl fumarate (DMF;
also known as gastro-resistant DMF) is a novel,
oral MS therapeutic approved for the treatment
of patients with relapsing forms of MS.
Treatment with DMF has been shown in 2
pivotal Phase 3 trials (DEFINE and CONFIRM) to
result in significant reductions in clinical and
MRI activity and have a favorable benefit–risk
profile in patients with RRMS [17, 18]. In a post
hoc analysis of integrated data from DEFINE
and CONFIRM, DMF demonstrated strong
efficacy across a broad range of clinical and
neuroradiologic outcome measures in patients
newly diagnosed with RRMS [19]. Throughout a
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2-year period, DMF 240 mg twice (BID) and
thrice daily (TID) resulted in reduced
annualized relapse rate (ARR), risk of relapse,
proportion of newly diagnosed patients with
12-week confirmed disability progression, odds
of having more gadolinium-enhancing (Gd?)
lesions, mean number of new or enlarging
T2-hyperintense lesions, and mean number of
new non-enhancing T1-hypointense lesions
compared with placebo (PBO).
ENDORSE is an ongoing, 8-year extension
study of DEFINE and CONFIRM that is being
conducted to evaluate the long-term safety and
efficacy of DMF in patients with RRMS. The
purpose of this paper is to report 6-year clinical
efficacy by integrating data from DEFINE,
CONFIRM and ENDORSE, to investigate the
long-term efficacy of DMF in newly diagnosed
patients with RRMS. In addition, summary
safety of DMF was also assessed.
METHODS
Patients and Study Design
ENDORSE (ClinicalTrials.gov identifier:
NCT00835770) is a 2-phase extension study
of the DEFINE (ClinicalTrials.gov identifier:
NCT00420212) [17] and CONFIRM
(ClinicalTrials.gov identifier: NCT00451451)
[18] Phase 3 studies, with a total of 10 years of
planned follow-up (2 years in the parent
studies, DEFINE and CONFIRM, plus 8 years
extension in ENDORSE). Further details have
been previously reported [19].
DEFINE and CONFIRM included patients
18–55 years of age with RRMS confirmed using
McDonald [20] diagnostic criteria. Eligible
individuals must also have an Expanded
Disability Status Scale (EDSS) [21] score of
0–5.0, inclusive and evidence of disease
activity (i.e., relapsed 1 or more times during
the year prior to randomization with a prior
brain MRI demonstrating 1 or more lesions
consistent with MS, or 1 or more Gd? lesions
detected by brain MRI within 6 weeks of
randomization). Key exclusion criteria
included relapse or corticosteroid treatment
within 50 days prior to randomization or prior
treatment with GA within 3 months prior to
randomization (DEFINE) or at any time
(CONFIRM).
In ENDORSE, patients were eligible to enroll
if they had participated in and completed, as
per protocol, 1 of the 2-year parent studies.
Patients were excluded from participating in
ENDORSE if there had been any significant
change in medical history; if the patient
discontinued oral study treatment in the
parent studies due to an adverse event (AE) or
other reason (except protocol-defined relapse/
disability progression); or if alanine
transaminase, aspartate aminotransferase, or
gamma-glutamyl transpeptidase increased to
greater than 3 times the upper limit of normal.
The ENDORSE extension study was initiated
as a multicenter, parallel-group, randomized,
dose-blind, dose-comparison study. Patients
were enrolled in ENDORSE at Week 96 (last
visit of the parent study), which served as the
baseline visit for the extension study. In the first
phase of ENDORSE, patients who received
240 mg DMF BID or TID in either parent study
remained on their same DMF dosage. Patients
who received PBO (DEFINE and CONFIRM) or
GA (CONFIRM) were re-randomized 1:1 to
240 mg DMF BID or TID. Patients were
followed every 4 weeks for the first 24 weeks of
ENDORSE and every 12 weeks thereafter for up
to 8 years. Subsequent to the initiation of
ENDORSE, DMF was approved in several
countries for the treatment of MS at a dose of
240 mg BID. Effective with the approval, the
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ENDORSE protocol (March 2014) was amended,
initiating the second phase. In the second
phase, participants receiving DMF 240 mg TID
were switched to DMF 240 mg BID dosing at
their next scheduled visit.
Efficacy Assessments
The primary efficacy endpoints were the
proportion of patients relapsed at 2 years in
DEFINE and ARR at 2 years in CONFIRM.
Additional efficacy endpoints included 2-year
assessment of time to 12-week confirmed
disability progression and numbers of Gd?,
new or enlarging T2-hyperintense, and new
T1-hypointense lesions. Neurologic exams
occurred every 12 weeks for efficacy
assessments and at the time of suspected
relapse. Relapses were defined as new or
recurrent neurologic symptoms, not associated
with fever or infection, lasting at least
24 h and accompanied by new objective
neurologic findings. Relapses were confirmed
by an Independent Neurologic Evaluation
Committee. MRI scans were obtained at
baseline and at Weeks 24, 48, and 96. The
primary objective of ENDORSE was to evaluate
the long-term safety profile of DMF in patients
with RRMS. Long-term efficacy outcomes (e.g.,
ARR, 24-week confirmed EDSS progression)
were considered secondary objectives.
Patients diagnosed with RRMS per McDonald
diagnostic criteria [20] within 1 year prior to
entry into DEFINE and CONFIRM and were
either treatment-naı¨ve or previously treated
with corticosteroids alone comprised the
newly diagnosed population. Prior to the
analysis being conducted, the 1-year criterion
was chosen because it is the median time since
diagnosis of RRMS in the overall
treatment-naı¨ve population. Clinical efficacy
endpoints were evaluated in post hoc analyses
and included ARR and disability progression
based on the EDSS score, which was measured
every 6 months.
Statistical Analysis
Integrated data from DEFINE, CONFIRM, and
ENDORSE were used in this post hoc analysis.
This report, based on the 6-year interim analysis
conducted April 15, 2015, presents the
long-term efficacy of DMF using clinical
endpoints, and it was based on patients who
received 1 or more doses of DMF in ENDORSE
and had 1 or more post-baseline assessments of
the efficacy parameter being analyzed
[intent-to-treat (ITT) population]. The analyses
were generally based on all observed data prior
to switching patients to alternative MS
therapies. Clinical efficacy results are
summarized for Years 1 and 2 of the parent
studies (DEFINE and CONFIRM) and Years 1, 2,
3, and 4 for the cohort of patients who
participated in the ENDORSE extension study.
Data are presented according to treatment
received in the parent and extension studies.
Our analysis focused on DMF BID, as this
represents the approved dosage. Patients who
received GA were excluded from the analysis
since DEFINE did not include a GA-comparator
arm and CONFIRM was not designed to
compare DMF with GA.
ARR was defined as the total number of
relapses divided by the number of patient-years
in the study. Data (excluding any collected after
patients were switched to alternative MS
medications) was analyzed using a negative
binomial regression model adjusted for
baseline age (\40 vs. C40 years), number of
relapses in the year prior to study entry, baseline
EDSS score (B2.0 vs. [2.0), and region
pre-defined based on geography, type of
health care system, and access to health care
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(1 = United States; 2 =Western Europe,
Canada, Costa Rica, Australia, New Zealand,
Israel, and South Africa; or 3 = Eastern Europe,
India, Guatemala, and Mexico). Disability as
measured by time to 24-week confirmed
EDSS progression was analyzed using a
Cox proportional hazards model, adjusted for
the following covariates: baseline EDSS
score (B2.0 vs. [2.0), baseline age
(\40 vs. C40 years), region, and number of
relapses in the year prior to study entry.
Analyses were performed using SAS version
9.3 software (SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Study Population
The DEFINE and CONFIRM study populations
included 444 patients treated with PBO or DMF
240 mg BID who met the criteria for newly
diagnosed, of whom 362 completed the parent
study (189 PBO and 173 DMF) [19]. Of these
patients, 229 entered the ENDORSE extension
study and were included in the present analysis:
144 continued on DMF 240 mg BID treatment
throughout the duration of DEFINE/CONFIRM
and ENDORSE (DMF/DMF) and 85 received PBO
in DEFINE/CONFIRM for 2 years and then
switched to DMF 240 mg BID in ENDORSE
(PBO/DMF; Table 1). Of these patients, 106
DMF/DMF patients and 62 PBO/DMF patients
were female. There was a median (range)
follow-up duration of 75.0 (23.0–97.0) months
in DMF/DMF patients and 75.0 (14.0–97.3)
months in PBO/DMF patients. All treatment
groups had a mean (standard deviation) time
since diagnosis of 0.5 (0.5) years. In the PBO/
DMF and DMF/DMF groups, 7.1% and 9.7% of
patients, respectively, received prior steroid
treatment. DMF/DMF patients remaining on
the study received C6 years of continuous DMF
treatment, while PBO/DMF patients received
2 years of PBO (DEFINE/CONFIRM) followed by
C4 years of DMF (ENDORSE).
Clinical Efficacy
In the newly diagnosed population, DMF
treatment significantly reduced the frequency
of relapse. Over the 6-year duration, including
DEFINE/CONFIRM and the ENDORSE
extension, the cumulative ARR was
numerically lower in patients who received
continuous BID treatment (DMF/DMF) than in
those who received delayed treatment (PBO/
DMF); cumulative ARRs [95% confidence
interval (CI)] were 0.137 (0.101, 0.186) and
0.168 (0.113, 0.252) for DMF/DMF and PBO/
DMF patients, respectively (Fig. 1a). The rate
ratio (95% CI) was 0.81 (0.51, 1.31),
corresponding with a 19% risk
reduction (P = 0.3988). Patients who received
delayed treatment (PBO/DMF) demonstrated
improvements after switching to DMF in
ENDORSE (Fig. 1b). The ARR (95% CI) for PBO/
DMF patients, from Years 0–2 (DEFINE/
CONFIRM; while on PBO) was 0.260 (0.182,
0.372), which then decreased to 0.102 (0.064,
0.163) after switching to DMF in ENDORSE and
receiving treatment throughout the next 4 years
(rate ratio: 0.39; 95% CI: 0.24, 0.63). This
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represented a 61% risk reduction for Years 3–6
versus Years 1–2 (P\0.0001).
The risk of 24-week confirmed disability
progression throughout 6 years was
substantially reduced among newly diagnosed
patients receiving continuous DMF BID
treatment (DMF/DMF) compared with those
switching from PBO to DMF BID (Fig. 2). Based
on Kaplan–Meier estimates, the proportion
(95% CI) of patients with 24-week confirmed
disability progression as measured by EDSS was
15.7% (10.3%, 23.7%) in DMF/DMF patients
and 24.3% (15.9%, 36.2%) in the PBO/DMF
treatment group after 6-year minimum
follow-up (hazard ratio: 0.51; 95% CI: 0.27,
0.97), which represented a 49% risk reduction
for DMF/DMF versus PBO/DMF (P = 0.0397).
The overall event rate of EDSS progression
remains low; therefore, median EDSS scores
remained stable over the study period.
Specifically, the median EDSS at the end of
6 years remained 2.0, the same as the median
EDSS at baseline.
AEs
In the newly diagnosed population, overall
incidence of AEs was similar between PBO/
DMF-treated (94%) and DMF/DMF-treated
patients (92%; Table 2). AEs reported most
frequently in patients receiving continuous
DMF BID included MS relapse,
nasopharyngitis, upper respiratory tract
infection, urinary tract infection, and flushing.
The most common AE reported by patients new
to DMF treatment in ENDORSE included
Table 1 Baseline demographic and disease characteristics of the newly diagnosed population at the start of DEFINE
and CONFIRM
Characteristica DMFb/DMFb (n5 144) PBO/DMFb (n5 85)
Age, years 35.5 (9.2) 36.7 (9.1)
Female (%) 106 (73.6) 62 (72.9)
Time since ﬁrst MS symptoms (years) 4.6 (6.2) 4.6 (5.4)
Median (min, max) 2.0 (0.0, 42.0) 2.0 (0.0, 31.0)
Time since diagnosis (years) 0.5 (0.5) 0.5 (0.5)
Median (min, max) 0.0 (0.0, 1.0) 1.0 (0.0, 1.0)
Patients with prior treatment with corticosteroids, n (%) 14 (9.7) 6 (7.1)
Relapses in prior year 1.4 (0.6) 1.3 (0.5)
EDSS score 2.1 (1.2) 2.2 (1.0)
Gd? lesion volume (cm3)c 0.4 (1.1) 0.2 (0.3)
T2-hyperintense lesion volume (cm3)c 8.5 (9. 5) 7.0 (6.2)
T1-hypointense lesion volume (cm3)c 2.5 (3.7) 1.8 (2.0)
EDSS Expanded Disability Status Scale, Gd? gadolinium-enhancing,MRI magnetic resonance image,MS multiple sclerosis,
PBO placebo
a Values are mean (standard deviation) unless otherwise stated
b DMF delayed-release dimethyl fumarate (also known as gastro-resistant DMF)
c MRI cohort only
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flushing, MS relapse, and headache. In the
DMF/DMF and PBO/DMF groups, 9% and
18%, respectively, discontinued study
treatment due to AEs. Rates of discontinuation
due to individual AEs in were low (B2% for
individual AEs in each treatment group).
DISCUSSION
DMF showed strong and sustained efficacy
across a spectrum of clinical outcomes in
newly diagnosed patients with RRMS in this
post hoc analysis of integrated data from
DEFINE, CONFIRM, and ENDORSE patients
having a 6-year minimum follow-up. Patients
receiving continuous DMF treatment
experienced sustained clinical effects on ARR
throughout 6 years of follow-up. DMF
treatment also resulted in clinical benefits for
patients who switched from PBO to receiving
DMF BID treatment for 4 years, as evidenced by
reduced ARR following the switch. Importantly,
patients receiving continuous DMF treatment
had substantially lower risk for 24-week
confirmed disability progression compared
with those receiving delayed treatment. This
benefit was sustained with 6 years of minimum
follow-up.
The effects of DMF in the newly diagnosed
population were numerically stronger than
those seen in the overall ITT population of
ENDORSE [22] and consistent with findings
from previous integrated studies of DEFINE
and CONFIRM [19]. Although limited, these
results support the notion that intervention at
the early stages of RRMS may improve
treatment outcomes. Indeed, it has been
reported that acute exacerbations of MS have a
Fig. 1 Cumulative ARR. ARR was calculated using a
negative binomial regression model, adjusted for baseline
Expanded Disability Status Scale (B2.0 vs.[2.0), baseline
age (\40 vs. C40 years), region, and number of relapses in
the 1 year prior to DEFINE/CONFIRM study entry.
aDMF delayed-release dimethyl fumarate (also known as
gastro-resistant DMF). bBased on a repeated negative
binomial model for estimated 0–2/3–6 years ARR. ARR
annualized relapse rate, CI conﬁdence interval, PBO
placebo
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sustained effect on accrued impairment in MS
[23]. Therefore, decreasing the total number of
events experienced in a lifetime may reduce the
overall impairment, underlying improved
long-term outcomes from earlier treatment.
It should be noted that the newly diagnosed
cohort assessed in this analysis was limited by
the small sample size and the post hoc nature of
the analysis. As with other long-term extension
trials [24, 25], bias could also result from the
disproportionate discontinuation of patients
who experienced suboptimal efficacy or AEs
during the ENDORSE extension period,
although the impact would be expected to be
similar between the two arms, or because not all
patients completing DEFINE and CONFIRM
chose to enroll in ENDORSE. Therefore, results
of the present analysis should be interpreted
with caution.
Access of the central nervous system by
autoreactive lymphocytes is thought to trigger
a cascade of events that initiate the
demyelination, axonal transection, and
neurodegeneration associated with RRMS. This
is followed by extensive neuronal loss and
gliosis in later stages [7, 26]. Therefore,
therapeutic interventions in newly diagnosed
patients with RRMS may have the greatest
potential to slow the accumulation of damage
in the long term. This assertion is supported by
findings that long-term outcomes are poorer in
patients with a greater frequency of relapse and
higher lesion load in early MS [27–29]. This
evidence supports the notion that the
opportunity for maximal therapeutic effect has
an early window, with the association between
MS disease activity and long-term clinical
prognosis becoming attenuated over time. [28,
Fig. 2 Proportion of patients with 24-week conﬁrmed
disability progression. Conﬁrmed progression of disability is
deﬁned as[1.0-point increase on EDSS from a baseline
EDSS[1.0 conﬁrmed for 24 weeks or[1.5-point increase
on EDSS from a baseline EDSS of 0 conﬁrmed for
24 weeks. Patients were censored if they withdrew from the
study or switched to alternative MS medication without a
progression. aDMF delayed-release dimethyl fumarate (also
known as gastro-resistant DMF). EDSS Expanded
Disability Status Scale, HR hazard ratio, PBO placebo
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29]. Furthermore, MRI and pathological data
support MS causing axonal damage even when
there are no clinical signs of the disease [30].
Consequently, a number of guidelines,
including those issued by the National
Multiple Sclerosis Society, recommend early
intervention as standard of care [31–33].
Currently, there are no universal criteria for
defining ‘newly diagnosed’. Newly diagnosed
patients have been variously defined using
several criteria, either alone or in
combination: time from symptom onset or
diagnosis, EDSS score, clinical presentation
(consistent with CIS), and progression from
CIS to CDMS. Time since diagnosis is the most
varied of the newly diagnosed criteria; this
duration of time has varied from as short as
immediately following diagnosis [34] to as long
as 8–10 years after diagnosis [35, 36]. For the
purpose of this study, the newly diagnosed
patients were initially described as being
diagnosed with RRMS per McDonald criteria
[20] within 1 year from study entry. Inherent in
the ENDORSE study design, this analysis
assesses newly diagnosed patients treated with
DMF at 2 different times from diagnosis with
RRMS. DMF/DMF patients received DMF
treatment within 1 year of diagnosis.
Meanwhile, PBO/DMF patients received DMF
treatment within 3 years of diagnosis. It is
important to note patients analyzed within
this study have already progressed past the CIS
and CDMS stages of MS and were either
treatment-naı¨ve or previously treated with
corticosteroids alone.
Based on this post hoc analysis, DMF
demonstrated a safety and tolerability profile
in newly diagnosed patients that was
comparable with that of the ENDORSE overall
safety population [37]. Flushing,
nasopharyngitis, and MS relapse were among
the most common AEs reported by both DMF/
DMF and PBO/DMF newly diagnosed patients.
In the overall ENDORSE safety population, the
Table 2 Overall incidence of AEs (occurring at an incidence of C10%) in the newly diagnosed population
Event DMFa/DMFa (n5 144) PBO/DMFa (n5 85)
Any AE, n (%) 132 (92) 80 (94)
MS relapse 41 (28) 22 (26)
Nasopharyngitis 39 (27) 12 (14)
Flushing 21 (15) 26 (31)
Upper respiratory tract infection 29 (20) 11 (13)
Urinary tract infection 24 (17) 9 (11)
Headache 20 (14) 14 (16)
Diarrhea 20 (14) 11 (13)
Back pain 19 (13) 9 (11)
Fatigue 13 (9) 10 (12)
Upper abdominal pain 5 (3) 9 (11)
Pain in extremity 15 (10) 7 (8)
AE adverse event, MS multiple sclerosis, PBO placebo
a DMF delayed-release dimethyl fumarate (also known as gastro-resistant DMF)
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most common AEs were MS relapse and
nasopharyngitis in the DMF/DMF patients,
while flushing and gastrointestinal (GI)-related
events were more common among patients
previously treated with PBO and new to DMF
treatment [37]. This is not surprising given the
well-known observation that flushing and
GI-related events tended to be transient and
decrease substantially after the first 1–2 months.
The incidence of AEs leading to discontinuation
were higher in newly diagnosed patients with
RRMS who were new to DMF in ENDORSE
(PBO/DMF; 18%) compared with those
receiving continuous treatment (DMF/DMF;
9%). This is consistent with the overall
population, in which 17% of PBO/DMF and
7% DMF/DMF patients discontinued due to
AEs. The observation that a higher proportion
of patients new to DMF discontinued due to
AEs, in both the newly diagnosed and overall
population, can largely be explained by the
occurrence of flushing and GI events that tend
to occur early in therapy with DMF [17, 18, 38].
Rates of discontinuation due to individual
GI-related AEs were similar in patients new to
DMF in the newly diagnosed cohort compared
with the overall population (B3% discontinued
due to individual GI-related AEs). Among
patients new to DMF, 4% and 0%
discontinued due to flushing in the overall
population and newly diagnosed cohort,
respectively. In patients continuing DMF, B1%
of patients each discontinued due to flushing or
GI-related events in both the overall population
and the newly diagnosed cohort.
CONCLUSIONS
After 6 years minimum follow-up in patients
who received continuous DMF treatment
(2 years in DEFINE or CONFIRM, followed by
4 years in ENDORSE), the ARR and the
proportion of patients with confirmed
disability progression remained low: from
Years 0–6, the ARR was 0.137 (95% CI 0.101,
0.186) and the proportion of patients with
disability progression was 15.7% (95% CI
10.3%, 23.7%). In patients who switched from
PBO (Years 0–2) to DMF (Years 3–6), the ARR
was significantly reduced (61% risk reduction)
after switching to DMF. Importantly, patients
receiving continuous DMF treatment had
substantially lower risk for 24-week confirmed
disability progression over the course of 6 years
compared with those who received delayed
treatment. Together, results of this post hoc
analysis show that treatment with DMF results
in strong and sustained clinical effects in newly
diagnosed patients with RRMS and suggest
greater benefit with early initiation of
treatment in this patient population. However,
results should be interpreted with caution as the
sample size was small in the newly diagnosed
cohort.
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